home / stock / xbio / xbio quote
Last: | $4.01 |
---|---|
Change Percent: | -2.04% |
Open: | $3.82 |
Close: | $4.01 |
High: | $4.01 |
Low: | $3.82 |
Volume: | 2,664 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.01 | $3.82 | $4.01 | $4.01 | $3.82 | 2,664 | 07-05-2024 |
$3.7436 | $4.1047 | $3.7436 | $4.3114 | $3.7436 | 1,113 | 07-04-2024 |
$3.7436 | $4.1047 | $3.7436 | $4.3114 | $3.7436 | 1,113 | 07-03-2024 |
$4.1 | $4.1863 | $4.1 | $4.38 | $4.1 | 10,308 | 07-02-2024 |
$4.17 | $4.22 | $4.17 | $4.3199 | $3.7401 | 3,047 | 07-01-2024 |
$4.07 | $4.0101 | $4.07 | $4.2971 | $4.0101 | 4,908 | 06-28-2024 |
$4.15 | $3.74 | $4.15 | $4.365 | $3.7301 | 21,000 | 06-27-2024 |
$3.93 | $3.9443 | $3.93 | $3.9443 | $3.7401 | 1,565 | 06-26-2024 |
$3.83 | $3.93 | $3.83 | $4.08 | $3.82 | 4,321 | 06-25-2024 |
$4.2 | $4.5 | $4.2 | $4.5 | $4.2 | 3,994 | 06-24-2024 |
$4.46 | $4.11 | $4.46 | $4.46 | $4.11 | 3,370 | 06-21-2024 |
$4.015 | $4 | $4.015 | $4.0801 | $4 | 1,087 | 06-20-2024 |
$3.99 | $4.18 | $3.99 | $4.43 | $3.99 | 6,638 | 06-19-2024 |
$3.99 | $4.18 | $3.99 | $4.43 | $3.99 | 6,638 | 06-18-2024 |
$4.1099 | $3.79 | $4.1099 | $4.15 | $3.79 | 11,975 | 06-17-2024 |
$3.8598 | $3.9074 | $3.8598 | $3.9074 | $3.85 | 1,090 | 06-14-2024 |
$3.767 | $4.15 | $3.767 | $4.15 | $3.71 | 2,929 | 06-13-2024 |
$3.79 | $0 | $3.79 | $0 | $0 | 455 | 06-12-2024 |
$3.79 | $3.79 | $3.79 | $3.85 | $3.73 | 2,665 | 06-11-2024 |
$3.9 | $3.8001 | $3.9 | $3.9 | $3.8 | 2,612 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...